Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 122.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,369 shares of the company’s stock after purchasing an additional 4,610 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Viridian Therapeutics were worth $182,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of VRDN. Braidwell LP raised its holdings in shares of Viridian Therapeutics by 43.8% in the third quarter. Braidwell LP now owns 1,735,182 shares of the company’s stock worth $26,618,000 after buying an additional 528,882 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of Viridian Therapeutics by 1.9% in the 3rd quarter. Eagle Asset Management Inc. now owns 459,169 shares of the company’s stock valued at $7,044,000 after acquiring an additional 8,731 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Viridian Therapeutics by 170.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 313,217 shares of the company’s stock worth $4,805,000 after acquiring an additional 197,430 shares during the last quarter. Rafferty Asset Management LLC lifted its position in Viridian Therapeutics by 7.5% during the 3rd quarter. Rafferty Asset Management LLC now owns 262,296 shares of the company’s stock worth $4,024,000 after acquiring an additional 18,282 shares during the period. Finally, Wellington Management Group LLP grew its stake in Viridian Therapeutics by 25.2% during the 3rd quarter. Wellington Management Group LLP now owns 215,648 shares of the company’s stock valued at $3,308,000 after purchasing an additional 43,349 shares during the last quarter.

Analysts Set New Price Targets

VRDN has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Viridian Therapeutics in a research note on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and set a $30.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, March 20th. B. Riley dropped their price objective on shares of Viridian Therapeutics from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, March 21st. Finally, Wedbush raised their target price on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, Viridian Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $36.60.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $15.14 on Wednesday. The stock has a market capitalization of $966.23 million, a price-to-earnings ratio of -2.85 and a beta of 1.14. Viridian Therapeutics, Inc. has a 12 month low of $10.93 and a 12 month high of $28.35. The firm’s 50 day simple moving average is $16.65 and its 200-day simple moving average is $17.64. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.26 and a quick ratio of 18.26.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.37). The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.15 million. Viridian Therapeutics had a negative return on equity of 121.80% and a negative net margin of 75,711.48%. Viridian Therapeutics’s revenue for the quarter was down 31.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.13) EPS. Analysts expect that Viridian Therapeutics, Inc. will post -4.39 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.